Fulltext

Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance

Grigg MJ 1 , William T 2 , Piera KA 3 , Rajahram GS 2 , Jelip J 4 , Aziz A 3 Show all authors , Menon J 5 , Marfurt J 3 , Price RN 3 , Auburn S 3 , Barber BE 3 , Yeo TW 3 , Anstey NM 3

Affiliations 

  • 1 Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Casuarina, PO Box 41096, Darwin, NT, 0811, Australia. matthew.grigg@menzies.edu.au
  • 2 Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Kota Kinabalu, Sabah, Malaysia
  • 3 Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Casuarina, PO Box 41096, Darwin, NT, 0811, Australia
  • 4 Vector Disease Sector, Disease Control Division, Ministry of Health, Kuala Lumpur, Malaysia
  • 5 Clinical Research Centre, Queen Elizabeth Hospital, Ministry of Health, Kota Kinabalu, Sabah, Malaysia
Malar J, 2018 Dec 10;17(1):463.
PMID: 30526613 DOI: 10.1186/s12936-018-2593-x

Abstract

BACKGROUND: Spreading Plasmodium falciparum artemisinin drug resistance threatens global malaria public health gains. Limited data exist to define the extent of P. falciparum artemisinin resistance southeast of the Greater Mekong region in Malaysia.

METHODS: A clinical efficacy study of oral artesunate (total target dose 12 mg/kg) daily for 3 days was conducted in patients with uncomplicated falciparum malaria and a parasite count 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications